Clinical trials: Polycythemia Vera (PV)
Polycythemia Vera
Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study
The purpose of the RELIEF study is to compare symptoms in polycythemia vera (PV) subjects treated with ruxolitinib versus subjects treated with hydroxyurea (HU) as measured by the percent of subjects who achieve a clinically…
- Trial name
- NCT01632904
- Testing
- Ruxolitinib, Hydroxyurea (HU)
- Where
- 70 sites in United States, Belgium and 5 more
- Volunteers
- 110 people
- Sponsor
- Incyte Corporation
Myelofibrosis, Primary Myelofibrosis
Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis
This is a multicenter 2-part, Phase 1b study designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of PU-H71 in subjects taking concomitant ruxolitinib.
- Conditions
- Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- NCT03373877
- Testing
- PU-H71, Ruxolitinib
- Where
- 10 sites in United States
- Volunteers
- 4 people
- Sponsor
- Samus Therapeutics, Inc.
Polycythemia Vera
Study to Assess SLN124 in Patients With Polycythemia Vera
This is a Phase 1/2, multicenter study with an open-label dose escalation followed by a randomized placebo controlled and double-blind phase of SLN124 in adult patients with Polycythemia Vera (PV) to assess the safety…
- Trial name
- SLN (NCT05499013)
- Testing
- SLN124
- Where
- 28 sites in United States, Australia and 7 more
- Volunteers
- 69 people
- Sponsor
- Silence Therapeutics plc
Polycythemia Vera
PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
This is an open label, single arm trial of PTG-300 in subjects with PV who are newly diagnosed or for whom current therapy is not sufficient to control their hematocrit and have hematocrit >48% prior to dosing.
- Trial name
- PACIFIC (NCT04767802)
- Testing
- PTG-300
- Where
- 8 sites in Malaysia, South Korea
- Volunteers
- 20 people
- Sponsor
- Protagonist Therapeutics, Inc.
Polycythemia Vera, Essential Thrombocythemia
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
The purpose of the study is to isolate and characterize stem cells of patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not working the way they should be and why they seem to…
- Trial name
- NCT01970930
- Testing
- Blood specimen
- Where
- United States
- Volunteers
- 131 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera…
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
- Trial name
- FREEDOM (NCT03755518)
- Testing
- FEDRATINIB
- Where
- 35 sites in United States, Canada
- Volunteers
- 38 people
- Sponsor
- Celgene
Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis
RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00630994
- Testing
- Dacogen
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Mayo Clinic
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
This extension protocol to the core study CCL09101 allows patients who have tolerated the drug and derived a clinical benefit, to continue to receive treatment beyond the 9 cycles of the core protocol.
- Conditions
- Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01236638
- Testing
- Momelotinib
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 120 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Polycythemia Vera
MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera
The purpose of this Cohort Treatment Plan is to allow access to ruxolitinib for eligible patients diagnosed with Polycythemia Vera.
- Trial name
- NCT05269771
- Testing
- Ruxolitinib
- Where
- 25 sites in Australia, Belgium and 6 more
- Sponsor
- Novartis Pharmaceuticals
Polycythemia Vera (PV), Essential Thrombocythemia (ET)
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
The Philadelphia chromosome negative myeloproliferative neoplasms (MPN) comprise a group of clonal hematological malignancies that are characterized by chronic myeloproliferation, splenomegaly, different degrees of bone marrow…
- Trial name
- Ruxo-BEAT (NCT02577926)
- Testing
- Ruxolitinib, BAT
- Where
- 23 sites in Germany
- Volunteers
- 207 people
- Sponsor
- RWTH Aachen University
CALR Gene Mutation, Essential Thrombocythemia
CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential Thrombocythemia
This early phase I trial studies how well the use of a continuous positive airway pressure (CPAP) machine works in treating obstructive sleep apnea in patients with polycythemia vera or essential thrombocythemia.
- Conditions
- CALR Gene Mutation, Essential Thrombocythemia, JAK2 Gene Mutation, MPL Gene Mutation
- Trial name
- NCT03972943
- Testing
- Continuous Positive Airway Pressure, Patient Observation, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Utah
Polycythemia Vera
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV
A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV
- Trial name
- NCT05481151
- Testing
- P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)
- Where
- 23 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- PharmaEssentia
Essential Thrombocythemia, Polycythemia Vera
Efficacy and Safety of Peginterferon in ET and PV.
This is a single-arm, single-center study aims to recruit 40 participants with Essential Thrombocythemia (ET) and Polycythemia Vera (PV).
- Trial name
- NCT06734637
- Testing
- Peginterferon α-2b injection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhenya Hong
Polycythemia Vera
Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)
Polycythaemia vera (PV) is associated with a reduced quality of life, a high rate of vascular events, and an intrinsic risk of disease evolution.
- Trial name
- NCT06506084
- Testing
- Ropeginterferon alfa-2b
- Where
- 37 sites in Italy, Poland
- Volunteers
- 429 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Polycythemia Vera
AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.
Polycythemia Vera (PV) is a disease of bone marrow stem cells that manifests in a drastic increase of red blood cells and frequently also of white blood cells.
- Trial name
- CONTI-PV (NCT02218047)
- Testing
- Pegylated-Proline-interferon alpha-2b, Best available therapy (BAT)
- Where
- 47 sites in Austria, Bulgaria and 10 more
- Volunteers
- 170 people
- Sponsor
- AOP Orphan Pharmaceuticals AG
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF) The study will be conducted in 2 stages.
- Conditions
- Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
- Trial name
- NCT04878003
- Testing
- KRT-232, TL-895
- Where
- 29 sites in United States, Belarus and 7 more
- Volunteers
- 52 people
- Sponsor
- Kartos Therapeutics, Inc.
Polycythemia Vera
Treatment of Polycythemia Vera With Gleevec
The purpose of this research study is to evaluate the safety and effectiveness of patients with Polycythemia Vera treated with Gleevec.
- Trial name
- NCT01120821
- Testing
- Gleevec
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Weill Medical College of Cornell University